Activin-A is increasingly recognized as a potential therapeutic agent for conditions such as brain injury and inflammatory diseases. Studies have shown that it can help reduce damage and inflammation, ...

The first-hand experience of a biopharmaceutical researcher confirms this: “In our pharmacodynamics studies, we needed to inject recombinant proteins as candidate therapeutic drugs into mouse models.

Even trace amounts can compromise biological products, causing adverse reactions and regulatory headaches. Endotoxin-free recombinant proteins are the solution. What Are the Potential Risks of ...

Nuclera (Cambridge, UK) is a biotech company that specializes in rapid protein expression and purification optimization at the benchtop. With the aim of streamlining the drug discovery process, ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...

WALTHAM, MA - April 01, 2026 - - KACTUS, a biotechnology research reagent provider based in Waltham, Massachusetts, announced the commercial availability of ultra-low endotoxin recombinant human ...

Endotoxin-free proteins provide a more reliable choice for preclinical research, precise cellular experiments, and ...